
Knopp Biosciences, a US-based company, innovates breakthrough neurological disorder treatments, with a lead compound in development.
Knopp Biosciences is a drug discovery and development company based in Pittsburgh, United States, focused on delivering breakthrough treatments for neurological disorders. The company leverages innovation, experience, and partnerships to advance its mission. Knopp’s lead compound, KNS-760704, is in clinical development, and the company also manages a portfolio of equity securities and future product royalties. Their clinical-stage oral small molecule, dexpramipexole, is being developed for eosinophilic asthma by Areteia Therapeutics.
Knopp Biosciences has made significant strides in the field of drug discovery, particularly in challenging immunological and neurological diseases. Their Kv7 platform of small molecules is in the clinical stage, showcasing their commitment to advancing medical science. Notably, Areteia Therapeutics, a portfolio company of Bain Capital Life Sciences, is developing one of Knopp’s compounds, highlighting the company's impactful collaborations and contributions to innovative healthcare solutions.

KBP Biosciences
kbpbiosciences.com
Caden Biosciences

Bioscience Pharma Partners

Harmony Biosciences

Know Bio
knowbiollc.com

NeurOp

Escape Bio
escapebio.com

ReNeuroGen
rngen.com

Areteia Therapeutics
areteiatx.com

Nido Biosciences
nidobio.com

Neuropathix
neuropathix.com

Intellect Neurosciences

Aptinyx
aptinyx.com

Kezar Life Sciences

Novoron Bioscience
novoron.com
Companies similar to Knopp Biosciences include KBP Biosciences, Caden Biosciences, Bioscience Pharma Partners and Harmony Biosciences.
Knopp Biosciences was founded in 2004.
Knopp Biosciences' headquarters is located in Pittsburgh, PA, US.
Knopp Biosciences' most recent funding round was for $14M (USD) in November 2020.
As of Nov 11, 2020, Knopp Biosciences has raised a total of $164M (USD).
Knopp Biosciences has 10 employees as of Feb 5, 2024.